Welcome to our dedicated page for Verve Therapeutics news (Ticker: VERV), a resource for investors and traders seeking the latest updates and insights on Verve Therapeutics stock.
Verve Therapeutics, Inc. (VERV) is a clinical-stage biotechnology pioneer developing single-course gene editing treatments for cardiovascular disease. This news hub provides investors and healthcare professionals with essential updates on therapeutic advancements, clinical trial progress, and strategic developments.
Access comprehensive coverage of VERV's innovative pipeline including PCSK9, ANGPTL3, and LPA gene editing programs. Our curated news collection features regulatory milestones, partnership announcements, and scientific breakthroughs in base editing technology.
Stay informed about Verve's cutting-edge approach to permanently modifying cholesterol-related genes through precise liver-targeted therapies. The page aggregates official press releases, trial result analyses, and expert commentary while maintaining strict financial compliance standards.
Bookmark this page for real-time updates on Verve Therapeutics' mission to transform cardiovascular care through durable genetic medicines. Check regularly for new developments in this rapidly evolving sector of precision biotechnology.
Verve Therapeutics, a clinical-stage company focused on genetic medicines for cardiovascular disease, has announced new equity awards granted on December 31, 2024. The company issued 5,330 restricted stock units (RSUs) to one new employee under its 2024 Inducement Stock Incentive Plan. This grant complies with Nasdaq Listing Rule 5635(c)(4) and serves as an inducement for employment. The RSUs will vest equally over four years, with annual installments beginning January 1, 2025, contingent on the employee's continued service with the company.
Verve Therapeutics, a clinical-stage biotechnology company focused on genetic medicines for cardiovascular disease, has granted 5,330 restricted stock units (RSUs) to a new employee under its 2024 Inducement Stock Incentive Plan. The grant, made on November 29, 2024, complies with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in equal annual installments over four years starting January 1, 2025, contingent on continued employment.
Verve Therapeutics reported progress in its clinical trials and Q3 2024 financial results. Seven participants were dosed in the Heart-2 Phase 1b trial of VERVE-102, with initial data expected in H1 2025. The first participant was dosed in the Pulse-1 Phase 1b trial of VERVE-201. The company reported $539.9M in cash and equivalents, with runway through 2026. Q3 financial results showed collaboration revenue of $6.9M, R&D expenses of $49.9M, and a net loss of $50.1M ($0.59 per share). VERVE-102 has been well-tolerated with no serious adverse events observed.
Verve Therapeutics has granted equity awards to six new employees as inducement for employment. The awards include 47,600 stock options with an exercise price of $5.73 per share and 42,710 restricted stock units (RSUs). The options have a 10-year term, vesting over four years with 25% vesting after one year and the remainder monthly over three years. The RSUs will vest in equal annual installments over four years starting January 1, 2025. These grants were made under the company's 2024 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Verve Therapeutics, a clinical-stage company developing genetic medicines for cardiovascular disease, has announced the granting of equity awards to five new employees on September 30, 2024. These awards, made under the company's 2024 Inducement Stock Incentive Plan, are in accordance with Nasdaq Listing Rule 5635(c)(4) and serve as an inducement for employment.
The equity awards consist of an aggregate of 33,280 restricted stock units (RSUs). These RSUs will vest in equal annual installments over four years, starting from October 1, 2024, contingent on the employees' continued service with Verve Therapeutics.
Verve Therapeutics, a clinical-stage company focused on developing genetic medicines for cardiovascular disease, has announced the granting of equity awards to two new employees. The awards, issued on August 30, 2024, consist of a total of 12,600 restricted stock units (RSUs). These grants were made under the company's 2024 Inducement Stock Incentive Plan and are in compliance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest in equal annual installments over a four-year period, starting from October 1, 2024, contingent on the employees' continued service with Verve Therapeutics. This move is part of the company's strategy to attract and retain talent in the competitive biotech sector.
Verve Therapeutics, a clinical-stage company developing genetic medicines for cardiovascular disease, reported Q2 2024 financial results and pipeline updates. Key highlights include:
- Heart-2 clinical trial of VERVE-102 enrolling in the U.K., Canada, and Australia
- VERVE-201 Phase 1b trial initiation on track for H2 2024
- Cash position of $575.9 million, runway into late 2026
- Q2 2024 revenue: $6.7 million; net loss: $49.8 million ($0.59 per share)
- R&D expenses: $51.0 million; G&A expenses: $14.5 million
The company plans to provide initial data from the Heart-2 trial and a PCSK9 program update in H1 2025, with Phase 2 trial initiation expected in H2 2025.
Verve Therapeutics, a clinical-stage company developing genetic medicines for cardiovascular disease, has announced the granting of equity awards to five new employees on July 31, 2024. These awards, made under the company's 2024 Inducement Stock Incentive Plan, include:
1. Stock options to purchase 91,200 shares of common stock at $7.00 per share, vesting over four years.
2. 37,300 restricted stock units (RSUs), vesting in equal annual installments over four years.
These grants are in accordance with Nasdaq Listing Rule 5635(c)(4) and are designed to serve as an inducement for new employees joining the company.
Verve Therapeutics, a clinical-stage biotech firm, announced the granting of equity awards to a new employee under its 2024 Inducement Stock Incentive Plan, as per Nasdaq Listing Rule 5635(c)(4). On June 28, 2024, the new hire received a stock option to purchase 76,900 shares at an exercise price of $4.88 per share, the closing price on the grant date. The option has a 10-year term, with 25% vesting on the first anniversary and the remainder vesting monthly over three years. Additionally, 19,200 restricted stock units (RSUs) were granted, set to vest in equal annual installments over four years from July 1, 2024, contingent on continued service.
Verve Therapeutics, a clinical-stage biotechnology company specializing in gene editing medicines for cardiovascular diseases, announced the appointment of Dr. Nia Tatsis and Jodie Morrison to its Board of Directors. Dr. Tatsis is the EVP, Chief Regulatory and Quality Officer at Vertex Pharmaceuticals, boasting extensive experience in regulatory affairs and quality control. Jodie Morrison, CEO of Q32 Bio, brings two decades of leadership in biopharmaceuticals, including successful mergers and IPOs. Their expertise will support Verve's ongoing clinical trials, including the Heart-2 trial for VERVE-102 targeting the PCSK9 gene and the initiation of the VERVE-201 trial targeting the ANGPTL3 gene.
